PT2361936T - Molécula que se liga a antigénio e utilizações desta - Google Patents
Molécula que se liga a antigénio e utilizações destaInfo
- Publication number
- PT2361936T PT2361936T PT101547511T PT10154751T PT2361936T PT 2361936 T PT2361936 T PT 2361936T PT 101547511 T PT101547511 T PT 101547511T PT 10154751 T PT10154751 T PT 10154751T PT 2361936 T PT2361936 T PT 2361936T
- Authority
- PT
- Portugal
- Prior art keywords
- molecule
- antigen
- connects
- connects antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10154751.1A EP2361936B1 (en) | 2010-02-25 | 2010-02-25 | Antigen-binding molecule and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2361936T true PT2361936T (pt) | 2016-07-15 |
Family
ID=42232726
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT101547511T PT2361936T (pt) | 2010-02-25 | 2010-02-25 | Molécula que se liga a antigénio e utilizações desta |
| PT11156113T PT2371866T (pt) | 2010-02-25 | 2011-02-25 | Molécula fv de ligação multivalente ao antigénio |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT11156113T PT2371866T (pt) | 2010-02-25 | 2011-02-25 | Molécula fv de ligação multivalente ao antigénio |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP2361936B1 (pt) |
| DK (1) | DK2371866T3 (pt) |
| ES (2) | ES2582001T3 (pt) |
| HR (1) | HRP20190288T1 (pt) |
| HU (1) | HUE041615T2 (pt) |
| LT (2) | LT2361936T (pt) |
| PL (2) | PL2361936T3 (pt) |
| PT (2) | PT2361936T (pt) |
| RS (1) | RS58352B1 (pt) |
| SI (1) | SI2371866T1 (pt) |
| SM (1) | SMT201900115T1 (pt) |
| TR (1) | TR201902400T4 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2613368C2 (ru) * | 2011-07-22 | 2017-03-16 | Аффимед Гмбх | Поливалентная антиген-связывающая fv-молекула |
| EP2970449B1 (en) * | 2013-03-15 | 2019-09-25 | Amgen Research (Munich) GmbH | Single chain binding molecules comprising n-terminal abp |
| SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| KR20170010863A (ko) | 2014-07-01 | 2017-02-01 | 화이자 인코포레이티드 | 이중특이성 이종이량체성 디아바디 및 이의 용도 |
| US20170335009A1 (en) * | 2014-10-31 | 2017-11-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent tlr9 bispecific antibody |
| HK1247215A1 (zh) | 2015-01-26 | 2018-09-21 | Macrogenics, Inc. | 包含dr5-结合结构域的多价分子 |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| AU2016298227B9 (en) | 2015-07-30 | 2019-10-31 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| AU2017382234B2 (en) | 2016-12-23 | 2025-01-30 | Macrogenics, Inc. | ADAM9-binding molecules, and methods of use thereof |
| CA3051062C (en) | 2017-02-28 | 2023-09-26 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
| CA3052886A1 (en) * | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Combination of an anti-cd16a antibody with a cytokine |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| EP3774914A2 (en) * | 2018-04-13 | 2021-02-17 | Affimed GmbH | Nk cell engaging antibody fusion constructs |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| DE10060140A1 (de) * | 2000-12-04 | 2002-06-06 | Vectron Therapeutics Ag Imt | Multimerer mehrfach-antigenbindender einzelkettiger Antikörper |
| EP1500665B1 (en) * | 2002-04-15 | 2011-06-15 | Chugai Seiyaku Kabushiki Kaisha | METHODS FOR CONSTRUCTING scDb LIBRARIES |
| ES2559763T3 (es) | 2002-09-10 | 2016-02-15 | Affimed Gmbh | Anticuerpo humano específico de CD3 con propiedades inmunosupresoras |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
-
2010
- 2010-02-25 LT LTEP10154751.1T patent/LT2361936T/lt unknown
- 2010-02-25 PT PT101547511T patent/PT2361936T/pt unknown
- 2010-02-25 EP EP10154751.1A patent/EP2361936B1/en active Active
- 2010-02-25 PL PL10154751.1T patent/PL2361936T3/pl unknown
- 2010-02-25 ES ES10154751.1T patent/ES2582001T3/es active Active
-
2011
- 2011-02-25 SM SM20190115T patent/SMT201900115T1/it unknown
- 2011-02-25 LT LTEP11156113.0T patent/LT2371866T/lt unknown
- 2011-02-25 PT PT11156113T patent/PT2371866T/pt unknown
- 2011-02-25 TR TR2019/02400T patent/TR201902400T4/tr unknown
- 2011-02-25 HU HUE11156113A patent/HUE041615T2/hu unknown
- 2011-02-25 PL PL11156113T patent/PL2371866T3/pl unknown
- 2011-02-25 RS RS20190201A patent/RS58352B1/sr unknown
- 2011-02-25 ES ES11156113T patent/ES2711377T3/es active Active
- 2011-02-25 EP EP11156113.0A patent/EP2371866B1/en active Active
- 2011-02-25 SI SI201131675T patent/SI2371866T1/sl unknown
- 2011-02-25 DK DK11156113.0T patent/DK2371866T3/en active
-
2019
- 2019-02-13 HR HRP20190288TT patent/HRP20190288T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR201902400T4 (tr) | 2019-03-21 |
| PL2371866T3 (pl) | 2019-05-31 |
| PL2361936T3 (pl) | 2016-10-31 |
| SI2371866T1 (sl) | 2019-04-30 |
| ES2711377T3 (es) | 2019-05-03 |
| EP2361936B1 (en) | 2016-04-20 |
| PT2371866T (pt) | 2019-02-27 |
| EP2361936A1 (en) | 2011-08-31 |
| LT2361936T (lt) | 2016-09-12 |
| EP2371866A3 (en) | 2013-06-26 |
| EP2371866B1 (en) | 2018-11-21 |
| HRP20190288T1 (hr) | 2019-04-05 |
| EP2371866A2 (en) | 2011-10-05 |
| DK2371866T3 (en) | 2019-03-18 |
| HUE041615T2 (hu) | 2019-05-28 |
| SMT201900115T1 (it) | 2019-02-28 |
| RS58352B1 (sr) | 2019-03-29 |
| ES2582001T3 (es) | 2016-09-08 |
| LT2371866T (lt) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2021036I2 (el) | Αντισωματα anti-angptl3 και χρησεις αυτων | |
| FR23C1023I2 (fr) | Anticorps anti-il-36r | |
| CY2020045I2 (el) | Anti-pd-l1 αντισωματα και χρησεις αυτων | |
| CY2025026I2 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| IL272831A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| CR20130406A (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| CO7010784A2 (es) | Moléculas que son anticuerpos con especificidad por ox40 humano | |
| IL231777B (en) | Antibodies against tl1a and uses thereof | |
| EP2530091A4 (en) | ANTI-DLL3 ANTIBODY | |
| EP2703486A4 (en) | ANTI-B7-H3 ANTIBODY | |
| EP2656211A4 (en) | SATISFACTION OF APPLICATION DEPENDENCIES | |
| DK2528621T3 (da) | Modificerede tuberkuloseantigener | |
| EP2794654A4 (en) | ANTI-PHF-TAU ANTIBODIES AND ITS USES | |
| EP2768858A4 (en) | ANTIBODIES AGAINST INFLUENZA | |
| HRP20180858T1 (hr) | Protutijela koja se vežu na ox40 i njihove uporabe | |
| EP2635605A4 (en) | ANTIBODIES TO HER3 AND COMPOSITIONS FROM THEREOF | |
| BR112012030311A2 (pt) | anticorpo | |
| HUE044089T2 (hu) | Neutralizáló anti-influenza A antitestek és alkalmazásaik | |
| DK2691443T3 (da) | Konjugerede lipomerer og anvendelser af disse | |
| PT2699264T (pt) | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 | |
| HRP20181320T8 (hr) | Ljudska anti-tau protutijela | |
| EP2520589A4 (en) | ANTI-CD27 ANTIBODY | |
| EP2934585A4 (en) | ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS |